natgillin/translations-raw huggingface dataset:
The nonwoven fabric of any one of the foregoing claims, wherein the calcium carbonate is present in the nonwoven fabric in an amount from 0. 
Netkani materijal prema bilo kojem od prethodnih zahtjeva, naznačen time da je kalcijev karbonat prisutan u netkanom materijalu u količini od 0.
2 to 40 wt.-%, and preferably from 1 to 35 wt.-%, based on the total weight of the nonwoven fabric. 
2 do 40 tež.-%, te poželjno od 1 do 35 tež.-%, bazirano na ukupnoj masi netkanog materijala.
forming the mixture into fibers and/or filaments having a diameter from 0.5 to 40 µm, and forming a nonwoven fabric from the fibers and/or filaments, wherein the calcium carbonate is present in the nonwoven fabric in an amount from 0.1 to 50 wt.-%, based on the total weight of the nonwoven fabric, wherein the polyester is a polyethylene terephthalate, and the calcium carbonate has an average particle size d50 from 1.2 to 1.8 µm, and a top cut particle size d98 from 4 to 7 µm. 
formiranje smjese u vlakna i/ili filamentna vlakna koja imaju promjer od 0.5 do 40 µm, i formiranje netkanog materijala iz vlakana i/ili filamentnih vlakana, pri čemu je kalcijev karbonat prisutan u netkanom materijalu u količini od 0.1 do 50 tež.-%, bazirano na ukupnoj masi netkanog materijala, pri čemu poliester je polietilen tereftalat, i kalcijev karbonat ima prosječnu veličinu čestica d50 od 1.2 do 1.8 µm, i veličinu čestica gornjeg reza d98 od 4 do 7 µm.
Use of calcium carbonate as filler in a nonwoven fabric comprising at least one polymer comprising a polyester, wherein the calcium carbonate is present in the nonwoven fabric in an amount from 0.1 to 50 wt.-%, based on the total weight of the nonwoven fabric, and wherein the nonwoven fabric comprises the at least one polymer and the at least one filler in form of fibers and/or filaments having a diameter from 0.5 to 40 µm, and wherein the polyester is a polyethylene terephthalate, and the calcium carbonate has an average particle size d50 from 1.2 to 1.8 µm, and a top cut particle size d98 from 4 to 7 µm. 
Uporaba kalcijevog karbonata kao punila u netkanom materijalu koji sadrži barem jedan polimer koji sadrži poliester, naznačena time da je kalcijev karbonat prisutan u netkanom materijalu u količini od 0.1 do 50 tež.-%, bazirano na ukupnoj masi netkanog materijala, te pri čemu netkani materijal sadrži barem jedan polimer i barem jedno punilo u obliku vlakana i/ili filamentnih vlakana koja imaju promjer od 0.5 do 40 µm, i pri čemu poliester je polietilen tereftalat, i kalcijev karbonat ima prosječnu veličinu čestica d50 od 1.2 do 1.8 µm, i veličinu čestica gornjeg reza d98 od 4 do 7 µm.
Use of fibers for the manufacture of a non-woven fabric, wherein the fibers comprise at least one polymer comprising a polyester and at least one filler comprising calcium carbonate, and wherein the polyester is a polyethylene terephthalate, and the calcium carbonate has an average particle size d50 from 1.2 to 1.8 µm, and a top cut particle size d98 from 4 to 7 µm. 
Uporaba vlakana za proizvodnju ne-tkanog materijala, naznačena time da vlakna sadrže barem jedan polimer koji sadrži poliester i barem jedno punilo koje sadrži kalcijev karbonat, i naznačena time da poliester je polietilen tereftalat, i kalcijev karbonat ima prosječnu veličinu čestica d50 od 1.2 do 1.8 µm, i veličinu čestica gornjeg reza d98 od 4 do 7 µm.
Apparatus according to claim 1, wherein the processing block comprises a microprocessor and at least one analogue/digital converter of such extracted signal. 
Uređaj u skladu s patentnim zahtjevom 1, pri čemu blok za obradu sadrži mikroprocesor i najmanje jedan analogni/digitalni pretvornik tako izlučenog signala.
Method for testing the insulation of a direct current track circuit in a railway line provided with a plurality of direct current track circuits adjacent to each other, such circuit comprising a pair of tracks (R) made up of parallel metal sections between which it is possible to apply an electric voltage, characterised in that it comprises the following steps: 
Metoda za ispitivanje izolacije strujnog kruga istosmjerne struje na željezničkoj liniji opskrbljenoj mnoštvom strujnih krugova istosmjerne struje koji su međusobno u neposrednoj blizini, takav se krug sastoji od para tračnica (R) načinjenih od paralelnih metalnih odsječaka između kojih je moguće primijeniti električni napon, karakterizirana na način da sadrži sljedeće korake:
A compound which decreases the intracellular concentration of chloride within neurons for use in the treatment of autism wherein said compound inhibits the Na-K-Cl (NKCC) co-transporter. 
Spoj koji smanjuje intracelularnu koncentraciju klorida unutar neurona za liječenje autizma, pri čemu navedeni spoj inhibira Na-K-Cl (NKCC) ko-transporter.
A compound for use according to the claim 1, wherein said compound is an inhibitor of NKCC1. 
Spoj za uporabu u skladu s patentnim zahtjevom 1, naznačeno time što navedeni spoj je inhibitor NKCC1.
A compound for use according to claim 1 or 2, wherein the compound is a diuretic. 
Spoj za uporabu u skladu s patentnim zahtjevom 1 ili 2, naznačeno time što spoj je diuretik.
A dental hand instrument of claim 3, wherein a height of the sickle-shaped recess corresponds to a height of the media channel. 
Ručni zubarski instrument u skladu s patentnim zahtjevom 3, karakteriziran na način da visina usjeka (11, 21) odgovara visini pridruženog središnjeg kanala.
A compound of formula (I): or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, for use in a method for treatment, management or prevention of a cancer of the blood or bone marrow, wherein: 
Tvar formule (II) [image] Ili njena farmaceutski prihvatljiva sol, solvat ili njen stereoizomer za uporabu u metodi za liječenje, zbrinjavanje ili sprječavanje raka kože, pluća, jajnika, prostate, debelog crijeva, rektuma, mozga, glave i vrata, grkljana, gušterače, kostiju, jetre ili žuči, pri čemu:
Compounds of formula I according to claim 1 and pharmaceutically acceptable salts, solvates, tautomers and stereoisomers thereof, including mixtures thereof in all ratios, for use in the treatment and/or prevention of cancer, multiple sclerosis, cardiovascular diseases, central nervous system injury and different forms of inflammation. 
Spojevi s formulom I prema zahtjevu 1 i njihove farmaceutski prihvatljive soli, solvati, tautomeri i stereoizomeri, uključujući njihove smjese u svim omjerima, naznačeni time da su za uporabu za liječenje i/ili prevenciju raka, multiple skleroze, kardiovaskularnih bolesti, ozljede središnjeg živčanog sustava i različitih oblika upala.
Compounds for use according to claim 8 for the treatment and/or prevention of diseases selected from the group cancer of head, neck, eye, mouth, throat, esophagus, bronchus, larynx, pharynx, chest, bone, lung, colon, rectum, stomach, prostate, urinary bladder, uterine, cervix, breast, ovaries, testicles or other reproductive organs, skin, thyroid, blood, lymph nodes, kidney, liver, pancreas, brain, central nervous system, solid tumors and blood-borne tumors. 
Spojevi za uporabu prema zahtjevu 8 naznačeni time da su za liječenje i/ili prevenciju bolesti koje se biraju iz skupine koju čine karcinom glave, vrata, oka, usta, grla, jednjaka, bronha, grkljana, ždrijela, prsnog koša, kostiju, pluća, debelog crijeva, rektuma, želuca, prostate, mokraćnog mjehura, maternice, grlića maternice, dojke, jajnika, testisa ili drugih reproduktivnih organa, kože, štitnjače, krvi, limfnih čvorova, bubrega, jetre, gušterače, mozga, središnjeg živčanog sustava, solidnih tumora i hematopoetskih tumora.
A compound represented by the formula (I): and racemates, enantiomers, diastereomers, tautomers, polymorphs, pseudopolymorphs and pharmaceutically acceptable salts, thereof. 
Spoj, naznačen time što ga prikazuje formula (I): [image], te njegovi racemati, enantiomeri, dijastereomeri, tautomeri, polimorfi, pseudopolimorfi i farmaceutski prihvatljive soli.
the compound of claim 1 or claim 2; and a P2Y2 receptor agonist. 
spoj u skladu s patentnim zahtjevom 1 ili patentnim zahtjevom 2; i agonist receptora P2Y2.
A composition, comprising: the compound of claim 1 or claim 2; and 
spoj u skladu s patentnim zahtjevom 1 ili patentnim zahtjevom 2; i bronhodilator.
a bronchodilator. The compound of claims 1 or 2 for use in promoting hydration of mucosal surfaces, wherein an effective amount of the compound of claims 1 or 2 is administered to a mucosal surface of a subject. 
Spoj u skladu s patentnim zahtjevima 1 ili 2, naznačen time što je namijenjen upotrebi u poticanje vlaženja površine sluznice, gdje se djelotvornu količinu spoja u skladu s patentnim zahtjevima 1 ili 2 primjenjuje na površinu sluznice subjekta.
A composition comprising an osmolyte and the compound of claims 1 or 2 for use in treating one or more conditions selected from the group consisting of chronic bronchitis, bronchiectasis, cystic fibrosis, sinusitis, vaginal dryness, dry eye, Sjogren's disease, distal intestinal obstruction syndrome, dry skin, esophagitis, dry mouth (xerostomia), nasal dehydration, asthma, primary ciliary dyskinesia, otitis media, chronic obstructive pulmonary disease, emphysema, pneumonia, diverticulitis, rhinosinusitis, and airborne infections. 
Pripravak koji sadrži osmolit i spoj u skladu s patentnim zahtjevima 1 ili 2, naznačen time što je namijenjen upotrebi u liječenju jednog ili više stanja koja se bira iz skupine koju čine kronični bronhitis, bronhiektazija, cistična fibroza, sinusitis, suhoća vagine, suho oko, Sjögrenova bolest, sindrom opstrukcije distalnog crijeva, suha koža, ezofagitis, suha usta (kserostomija), dehidracija nosa, astma, primarna cilijarna diskinezija, upala srednjeg uha, kronična opstruktivna plućna bolest, emfizem, pneumonija, divertikulitis, rinosinusitis, te kapljične infekcije.
The composition for use of claim 8, wherein the compound is administered to a subject following administration of the osmolyte. 
Pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 8, naznačen time što se spoj primjenjuje na subjektu nakon primjene osmolita.
The composition for use of claim 8, wherein the osmolyte is sodium chloride which is delivered to a subject as a micronized particle of respirable size. 
Pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 8, naznačen time što je osmolit natrijev klorid, kojeg se unosi u subjekta kao mikronizirane čestice veličine pogodne za udisanje.
The composition for use of claim 8, wherein an effective amount of an osmolyte and a sodium channel blocker is administered to a subject by aerosolization using a device capable of delivering the formulation to the nasal passages or pulmonary airway wherein the aerosol is a respirable size. A composition, comprising: 
Pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 8, naznačen time što se djelotvornu količinu osmolita i blokator natrijevog kanala primjenjuje na subjektu aerosoliziranjem uz pomoć uređaja koji može unijeti formulaciju u nosne prolaze ili plućne dišne puteve, gdje je aerosol veličine pogodne za udisanje.
The compound of claims 1 or 2 for use in prophylactic, post-exposure prophylactic, preventive or therapeutic treatment against diseases or conditions caused by pathogens, wherein an effective amount of a compound of claims 1 or 2 is administered a subject in need of increased mucociliary clearance and mucosal hydration. 
Spoj u skladu s patentnim zahtjevima 1 ili 2, naznačen time što je namijenjen upotrebi u profilaksi, profilaksi nakon izlaganja, preventivnom ili terapijskom liječenju protiv bolesti ili stanja koja uzrokuju patogeni, gdje se djelotvornu količinu spoja u skladu s patentnim zahtjevima 1 ili 2 primjenjuje na subjektu kojem je potrebno pojačano čišćenje mukocilijarnog epitela i vlaženje sluznice.
A composition comprising an osmolyte and a compound of claims 1 or 2 for use in prophylactic, post-exposure prophylactic, preventive or therapeutic treatment against diseases or conditions caused by pathogens, wherein an effective amount of an osmolyte and a compound of claims 1 or 2 is administered to a subject in need of increased mucociliary clearance and mucosal hydration. 
Pripravak koji sadrži osmolit i spoj u skladu s patentnim zahtjevima 1 ili 2, naznačen time što je namijenjen upotrebi u profilaksi, profilaksi nakon izlaganja, preventivnom ili terapijskom liječenju protiv bolesti ili stanja koja uzrokuju patogeni, gdje se djelotvornu količinu osmolita i spoja u skladu s patentnim zahtjevima 1 ili 2 primjenjuje na subjektu kojem je potrebno pojačano čišćenje mukocilijarnog epitela i vlaženje sluznice.
Peptide compound according to claim 1, wherein Xaa1 is selected from the group consisting of a D-stereoisomer of charged amino acids, aromatic amino acids and hydrophobic amino acids. 
Peptidni spoj prema patentnom zahtjevu 1, naznačeno time što je Xaa1 izabran iz grupe koja se sastoji od D-stereoizomera naelektrisanih aminokiselina, aromatičnih aminokiselina i hidrofobnih aminokiselina.
Peptide compound according to claim 1 or 2, wherein Xaa1 is a hydrophobic amino acid, preferably wherein Xaa1 is Ile, Leu or Val. 
Peptidni spoj prema patentnom zahtjevu 1 ili 2, naznačeno time što je Xaa1 hidrofobna aminokiselina, pri čemu poželjno Xaa1 predstavlja Ile, Leu ili Val.
Peptide compound according to claim 1 or 2, wherein Xaa1 is an aromatic amino acid, preferably wherein Xaa1 is Tyr or Phe. 
Peptidni spoj prema patentnom zahtjevu 1 ili 2, naznačeno time što je Xaa1 aromatična aminokiselina, pri čemu poželjno Xaa1 predstavlja Tyr ili Phe.
A peptide compound according to any one of claims 1 to 10, for use in the treatment and/or prevention of a condition in which selective agonism of the AT2 receptor is desired and/or required. 
Peptidni spoj prema bilo kom od patentnih zahtjeva 1 do 10, za upotrebu u liječenju i/ili prevenciji stanja u kome je selektivni agonizam prema AT2 receptoru poželjan i/ili potreban.
A container (1) for transportation and/or storage of items, wherein: 
Spremnik (1) za prijevoz i/ili pohranu predmeta, pri čemu:
A container according to Claim 1 or Claim 2, wherein the container comprises a frame structure defining a base and a periphery. 
Spremnik prema zahtjevu 1 ili zahtjevu 2, naznačen time da spremnik sadrži strukturu okvira koja definira osnovicu i periferiju.
A container according to Claim 2, wherein the securing means is arranged to secure, for example by means of clamping, frame members of side by side adjacent containers. 
Spremnik prema zahtjevu 2, naznačen time da su sredstva za osiguravanje postavljena za osiguravanje, na primjer pomoću stezanja, elemenata okvira susjednih spremnika jednih uz druge.
the securing element (17) is pivotally mounted or hinged to be pivoted from the stowed to the deployed position; and/or ii) wherein the securing element (17) is configured for mating securing engagement with a complementary formation provided on the side by side positioned container. 
osiguravajući element (17) zglobno montiran ili zglobno spojen da se može zakretati iz spremljenog položaja u razvučeni položaj; i/ili ii) pri čemu je osiguravajući element (17) konfiguriran za pričvršćivanje spajanjem s komplementarnim oblikom koji je predviđen na spremnicima postavljenim jedan uz drugi.
the securing means is provided proximate the base of the container; and/or ii) the securing means is provided proximate the top of the container. 
sredstva za osiguravanje nalaze u blizini osnovice spremnika; i/ili ii) sredstva za osiguravanje se nalaze u blizini vrha spremnika.
A container according to claim 8, wherein a respective rotatable support member (10, 11) is provided for a respective tine guide (8, 9) and positioned adjacently thereto. 
Spremnik prema zahtjevu 8, naznačen time da je odgovarajući element rotirajućeg nosača (10, 11) predviđen za odgovarajuću zupčastu vodilicu (8, 9) i smješten susjedno u nju.
A container according to claim 9 or claim 10, wherein the tine guide includes a bracket formation or bracket mounting for the rotatable support member. 
Spremnik prema zahtjevu 9 ili zahtjevu 10, naznačen time da zupčasta vodilica obuhvaća strukturu nosača ili nosač za element rotirajućeg nosača.
A container according to any preceding claim, wherein; two pairs of opposed positioned tine guides (8, 9) are provided, a pair on each opposed side of the container; and/or 
su predviđena dva para suprotno smještenih zupčastih vodilica (8, 9), par na svakoj suprotnoj strani spremnika; i/ili ii) spremnik ima kratku širinu i relativno dugačku duljinu.
is selected from the group consisting of hydrogen and C1-C4alkyl; 
je odabran iz skupine koju čine vodik i C1-C4alkil;
and R12 are the same or different and are independently selected at each occurrence from the group consisting of hydrogen and C1-C4alkyl; 
i R12 su isti ili različiti i neovisno su odabrani prilikom svakog pojavljivanja, iz skupine koju čine vodik i C1-C4alkil;
is independently selected at each occurrence from the group consisting of hydrogen, methyl or ethyl. 
je neovisno odabran prilikom svakog pojavljivanja, iz skupine koju čine vodik, metil ili etil.
R13, is selected from the group consisting of hydrogen, C1-C4alkyl, and hydroxyC1-C4alkyl. 
je odabran iz skupine koju čine vodik, C1-C4alkil, i hidroksiC1-C4alkil.
is selected from the group consisting of CH2NHR13, CH2heterocycle, CH2OR15, and CH2S(O)2R17; and Ar2 is a five membered heteroaryl having 1 ring nitrogen atom and 0 or 1 additional ring heteroatoms selected from N and O and wherein said heteroaryl group is unsubstituted or substituted with 1 or 2 groups independently selected from the group consisting of C1-C4alkyl, C1-C4haloalkyl, halogen, hydroxyl, phenyl, and C3-C6cycloalkyl; 
je odabran iz skupine koju čine CH2NHR13, CH2heterocikl, CH2OR15, i CH2S(O)2R17; te Ar2 je peteročlani heteroaril koji ima jedan atom dušika u prstenu i nijedan ili jedan heteroatom prstena odabran od N i O, te je pritom navedena heteroaril-skupina nesupstituirana ili supstituirana s jednom ili dvije skupine neovisno odabrane iz skupine koju čine C1-C4alkil, C1-C4haloalkil, halogen, hidroksil, fenil, i C3-C6cikloalkil;
The compound of any one of claims 1-6, wherein R22 is selected from isopropyl, tert-butyl, cyclopropyl, cyclobutyl, 1-methyl-cyclopropyl, 1-trifluoromethyl-cyclopropyl, 1-ethyl-cyclopropyl, 1-methylcyclobutyl, 1-ethylcyclobutyl, and trifluoromethyl; and Z is O. 
Spoj prema bilo kojem od zahtjeva 1-6, naznačen time, da R22 je odabran od sljedećih izopropil, tert-butil, ciklopropil, ciklobutil, -metil-ciklopropil, 1-trifluorometil-ciklopropil, 1-etil-ciklopropil, -metilciklobutil, 1-etilciklobutil, i trifluorometil; te Z je O.
A combination, in particular a pharmaceutical combination, comprising a therapeutically effective amount of the compound according to any one of claims 1-12 and one or more additional therapeutically active agents. 
Kombinacija, posebno farmaceutska kombinacija, naznačena time, da obuhvaća terapeutski učinkovitu količinu spoja prema bilo kojem od zahtjeva 1-12 te jedno ili više dodatnih terapeutski djelotvornih sredstava.
Compound of any one of claims 1-12, or a salt thereof, for use in the treatment of a VEGF-R receptor dependent diseases selected from wet and dry age-related macular degeneration, geographic atrophy, central serous retinopathy, cystoid macular edema, diabetic retinopathy, proliferative diabetic retinopathy, diabetic macular edema, rubeosis iridis, Retinopathy of prematurity, Central and branch retinal vein occlusions, Inflammatory/infectious retinal neovascularization/edema, retinoblastoma, melanoma, ocular tumors, retinal detachment, myopic neovascularization, angiod streaks, Eales disease, ischemic retinopathy, choroidal rupture, contact lens wear, dry eye, blepharitis, corneal dystrophies, Trauma and previous surgery to the cornea, corneal bums, corneal graft rejection, Immunological corneal disease, and degenerative corneal diseases. 
Spoj prema bilo kojem od zahtjeva 1-12, ili njegova sol, naznačen/a time, da, da se upotrebljava u liječenju bolesti ovisnih o VEGF-R-receptoru, koje su odabrane od sljedećih: vlažna ili suha makularna degeneracija vezana za dob, geografska atrofija, centralna serozna retinopatija, cistoidni makularni edem, dijabetska retinopatija, proliferativna dijabetska retinopatija, dijabetski makularni edem, rubeosis iridis, retinopatija kod nedonoščadi, okluzije centralne i sporedne retinske vene, upalna/infektivna retinska neovaskularizacija/edem, retinoblastom, melanom, očni tumori, odvajanje retine, miopijska neovaskularizacija, angioidne brazde, Ealsova bolest, ishemijska retinopatija, koroidna ruptura, nošenje kontaktnih leća, suhe oči, blefaritis, distrofije rožnice, ozljeda i prethodne operacije na rožnici, opekotine rožnice, odbacivanje usatka rožnice, imunološka bolest rožnice, i degenerativne bolesti rožnice.
A t least two direct acting antiviral agents (DAAs) for use in a method for treatment of HCV infection, said method comprising administering at least two DAAs to an HCV patient, wherein neither interferon nor ribavirin are administered to said patient during said treatment, and said treatment lasts for 8, 9, 10, 11 or 12 weeks, and wherein said at least two DAAs comprise: or a pharmaceutically acceptable salt thereof, and or a pharmaceutically acceptable salt thereof. 
Najmanje dva antivirusna sredstva koja djeluju izravno (DAA) za primjenu u metodi za liječenje HCV infekcije, naznačena time, da navedeni postupak obuhvaća davanje najmanje dva DAA pacijentu koji boluje od HCV infekcije, pri čemu se navedenom pacijentu ne daje interferon niti ribavirin tijekom navedenog liječenja, a navedeni tretman traje 8, 9, 10, 11 ili 12 tjedana, i pri čemu navedeni najmanje dva DAA sadržavaju:
The at least two DAAs for the use of claim 1, wherein said treatment lasts for 8 weeks. 
Najmanje dva DAA za uporabu u skladu s patentnim zahtjevom 1, naznačena time, da navedeno liječenje traje 8 tjedana.
The at least two DAAs for the use of ay one of claims 1-14, wherein said at least two DAAs consist of (1) Compound 1 or a pharmaceutically acceptable salt thereof and (2) Compound 2 or a pharmaceutically acceptable salt thereof. 
Najmanje dva DAA za upotrebu prema bilo kojem od patentnih zahtjeva 1 do 14, naznačena time, da se navedena najmanje dva DAA sastoje od (1) Spoja 1 ili njegove farmaceutski prihvatljive soli i (2) Spoja 2 ili njegova farmaceutski prihvatljiva sol .
A compound for use according to claim 6 in the treatment or prevention of inflammatory disease, autoimmune disorder, cancer or multiple sclerosis and related disorders. 
Spoj za uporabu prema zahtjevu 6, naznačen time da je trza liječenje ili prevenciju upalne bolesti, autoimunog poremećaja, raka ili multiple skleroze i povezanih poremećaja.
A compound for use of claim 7 wherein the disease is selected from Rheumatoid Arthritis, Psoriatic arthritis, Osteoarthritis, Systemic Lupus Erythematosus, Lupus nephritis, Ankylosing Spondylitis, Osteoporosis, Systemic sclerosis, Multiple Sclerosis, Psoriasis, Type I diabetes, Type II diabetes, Inflammatory Bowel Disease (Cronh's Disease and Ulcerative Colitis), Hyperimmunoglobulinemia D and periodic fever syndrome, Cryopyrin-associated periodic syndromes, Schnitzler's syndrome, Systemic juvenile idiopathic arthritis, Adult's onset Still's disease, Gout, Pseudogout, SAPHO syndrome, Castleman's disease, Sepsis, Stroke, Atherosclerosis, Celiac disease, DIRA (Deficiency of IL-1 Receptor Antagonist), Alzheimer's disease, Parkinson's disease, Cancer. 
Spoj za uporabu prema zahtjevu 7, naznačen time da je bolest odabrana od reumatoidnog artritisa, psorijatičnog artritisa, osteoartritisa, sistemskog eritemskog lupusa, lupusnog nefritisa, ankiloznog spondilitisa, osteoporoze, sistemske skleroze, multiple skleroze, psorijaze, dijabetesa tip I, dijabetesa tip II, upalne bolesti crijeva (Crohnove bolesti i ulcerativnog kolitisa), Hiperimunoglobulinemija D i sindrom periodične groznice, periodičkih sindroma povezanih s kriopirinom, Schnitzlerovog sindroma, sistemski juvenilni reumatoidni artritis, Stillove bolesti odrasle dobi, gihta, pseudogihta, SAPHO sindroma, Castlemanove bolesti, sepse, moždanog udara, ateroskleroze, celijakije, DIRA (nedostatak antagonista receptora IL-1), Alzheimerove bolesti, Parkinsonove bolesti, raka.